Publications by authors named "Julie Hempel Larsen"
Article Synopsis
- The study analyzed data from the Empire HF trial to understand what factors influence physical activity levels in heart failure patients with reduced ejection fraction (HFrEF).
- It found that older age and anemia were linked to lower levels of accelerometer-measured physical activity, indicating that these factors negatively impact patients' activity.
- Additionally, while there was a slight increase in physical activity with improvements in self-reported health status, the correlation was weak, suggesting more research is needed to fully understand how activity levels relate to overall health.
Introduction: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have previously demonstrated cardioprotective properties in patients with type 2 diabetes, suggesting a preventive effect on heart failure (HF). The Empire Prevent trial program investigates the therapeutic potential for HF prevention by evaluating the cardiac, metabolic, and renal effects of the SGLT2 inhibitor empagliflozin in patients with increased risk of developing HF, but without diabetes or established HF.
Methods: The Empire Prevent trial program is an investigator-initiated, double-blind, randomized clinical trial program including elderly and obese patients (60-84 years, body mass index >28 kg/m) with at least one manifestation of hypertension, cardiovascular or chronic kidney disease, but no history of diabetes or HF.
Study Objective: The objective was to assess the effect of ongoing angiotensin receptor-neprilysin inhibitor(ARNI) on the effect of the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin on left ventricular (LV) size and function in patients with heart failure and reduced ejection fraction(HFrEF).
Design: Post hoc analysis of the Empire HF trial, an investigator-initiated, double-blind, randomized controlled trial.
Participants: 190 patients with HFrEF with New York Heart association class I-III symptoms with an ejection fraction of 40 % or below.